港股详情

本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

银诺医药－Ｂ

34.480

+1.5204.61%

成交量：43.86万

成交额：1,475.32万

市值：157.51亿

市盈率：-75.74

高：34.500

开：32.960

低：32.940

收：32.960

52周最高：74.000

52周最低：29.000

股本：4.57亿

香港流通股本：4.20亿

量比：1.01

换手率：0.10%

股息：- -

股息率：- -

每股收益(LYR):-0.455

净资产收益率：-23.27%

总资产收益率：-11.61%

市净率：21.10

市盈率(LYR):-75.74

市销率: 255.16

数据加载中...

总览公司新闻资讯公告

银诺医药-B(02591)：认购1.05亿元结构性存款产品

在全球市场展现非凡竞争力，浦东创新药精彩亮相上海生物医药创新成果展

银诺医药-B10月08日主力净流出121.8万元散户资金买入

银诺医药-B10月03日获主力加仓191.2万元

浦东生物医药企业竞逐“全球新”

银诺医药-B(02591)已在中国完成核心产品(即依苏帕格鲁肽α)用于治疗肥胖和超重的III期临床试验的首例患者给药

银诺医药-B09月30日主力净流出57.6万元散户资金买入

银诺医药-B：二零二五年中期报告

香港交易所

减肥神药核心专利明年到期，中国药企围剿全球药王

港股医药新锐布局AI

银诺医药-B09月22日主力净流入176.1万元散户资金抛售

迈富时携手银诺医药，以AI智能体驱动医药行业全链路智能升级

证券市场周刊

银诺医药-B09月18日主力净流出82.7万元散户资金买入

广州创新药，创造38亿账面回报

港股异动 | 银诺医药-B(02591)涨超4% 核心产品依苏帕格鲁肽α在澳门正式进入商业化销售阶段

银诺医药(02591.HK)核心产品在澳门正式进入商业化销售

阿斯达克财经

银诺医药-B(02591.HK)用于治疗2型糖尿病的核心产品于澳门的首张处方已在澳门华宝医疗中心开出

银诺医药-B(02591)用于治疗2型糖尿病的核心产品于澳门的首张处方已在澳门华宝医疗中心开出

浙商“股道行”||深耕江浙8月投研活动

浙商证券研究所

银诺医药-B(02591)认购结构性存款产品

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/hans/stock/02591/news?page=2"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"02591","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02591\",,,,,undefined,":{"symbol":"02591","market":"HK","secType":"STK","nameCN":"银诺医药－Ｂ","latestPrice":34.48,"timestamp":1763366893778,"preClose":32.96,"halted":0,"volume":438604,"delay":0,"floatShares":420285370,"shares":456819349,"eps":-0.4552777524427688,"marketStatus":"未开盘","change":1.52,"latestTime":"11-17 16:08:13","open":32.96,"high":34.5,"low":32.94,"amount":14753190,"amplitude":0.04733,"askPrice":34.48,"askSize":400,"bidPrice":34.32,"bidSize":200,"shortable":0,"etf":0,"ttmEps":-0.5774225878736056,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1763429400000},"marketStatusCode":0,"adr":0,"listingDate":1755187200000,"exchange":"SEHK","adjPreClose":32.96,"openAndCloseTimeList":[[1763343000000,1763352000000],[1763355600000,1763366400000]],"volumeRatio":1.006342,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02591\",,,,,undefined,":{"symbol":"02591","floatShares":420285370,"roa":"-11.61%","roe":"-23.27%","lyrEps":-0.455251,"volumeRatio":1.006342,"shares":456819349,"dividePrice":0,"high":34.5,"amplitude":0.04733,"preClose":32.96,"low":32.94,"week52Low":29,"pbRate":"21.10","psRate":"255.16","week52High":74,"institutionHeld":0,"latestPrice":34.48,"committee":-0.333333,"eps":-0.4552512595629902,"divideRate":0,"volume":438604,"delay":0,"ttmEps":-0.5773889873141231,"open":32.96,"prevYearClose":18.68,"prevWeekClose":32.96,"prevMonthClose":30.58,"prevQuarterClose":39.32,"fiveDayClose":32.3,"twentyDayClose":35.94,"sixtyDayClose":52.5},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/02591\",params:#limit:5,,,undefined,":[{"date":"2025-08-29","symbol":"02591","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1756431000000,"name":null,"time":"","dateTimestamp":1756396800000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"02591\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"02591\",market:\"HK\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/02591\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"02591","date":"2025-11-14","current":-59.386984,"percent":0.790323,"low":-137.156472,"twenty":-95.010372,"median":-77.299283,"eighty":-61.326336,"high":-56.144857,"avg":-80.581063,"sd":22.178352,"marketCap":15056765743},"quantilePoints":[{"date":"2025-08-15","current":-137.156472,"twenty":-137.156472,"median":-137.156472,"eighty":-137.156472,"marketCap":26152907730},{"date":"2025-08-22","current":-127.373977,"twenty":-129.344203,"median":-127.373977,"eighty":-126.417438,"marketCap":24211425497},{"date":"2025-08-29","current":-106.390102,"twenty":-127.373977,"median":-126.095992,"eighty":-114.007182,"marketCap":20319324643},{"date":"2025-09-05","current":-78.151342,"twenty":-127.373977,"median":-117.586994,"eighty":-99.491273,"marketCap":18939730209},{"date":"2025-09-12","current":-83.843855,"twenty":-126.417438,"median":-105.433356,"eighty":-83.374192,"marketCap":20355870191},{"date":"2025-09-19","current":-79.271387,"twenty":-126.095992,"median":-93.890147,"eighty":-81.90749,"marketCap":19232094592},{"date":"2025-09-26","current":-78.986763,"twenty":-125.916102,"median":-85.498552,"eighty":-79.429082,"marketCap":19113321562},{"date":"2025-10-03","current":-76.5387,"twenty":-122.116665,"median":-83.843855,"eighty":-78.76383,"marketCap":18565138343},{"date":"2025-10-10","current":-69.068341,"twenty":-116.871032,"median":-83.374192,"eighty":-77.810518,"marketCap":16728724560},{"date":"2025-10-17","current":-67.838616,"twenty":-109.436934,"median":-79.738352,"eighty":-74.826182,"marketCap":16418087403},{"date":"2025-10-24","current":-59.813644,"twenty":-105.816054,"median":-79.429082,"eighty":-68.576451,"marketCap":14481173363},{"date":"2025-10-31","current":-57.61442,"twenty":-103.460611,"median":-78.986763,"eighty":-66.346017,"marketCap":13969535692},{"date":"2025-11-07","current":-56.556997,"twenty":-100.097405,"median":-78.243448,"eighty":-63.14919,"marketCap":13704580470},{"date":"2025-11-14","current":-61.96171,"twenty":-95.010372,"median":-77.299283,"eighty":-61.326336,"marketCap":15056765743}],"updateTime":1763363005078},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"02591\",pageSize:20,pageCount:2,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2575216055","title":"银诺医药-B(02591)：认购1.05亿元结构性存款产品","url":"https://stock-news.laohu8.com/highlight/detail?id=2575216055","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575216055?lang=zh_cn&edition=fundamental","pubTime":"2025-10-14 21:45","pubTimestamp":1760449541,"startTime":"0","endTime":"0","summary":"智通财经APP讯，银诺医药-B(02591)发布公告，于2025年10月14日，公司及银诺技术(公司一间直接全资附属公司)以代价合共人民币1.05亿元(即其总本金额)向宁波银行认购一项银行结构性存款产品。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1355032.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02591","BK1161"],"gpt_icon":0},{"id":"2575237445","title":"在全球市场展现非凡竞争力，浦东创新药精彩亮相上海生物医药创新成果展","url":"https://stock-news.laohu8.com/highlight/detail?id=2575237445","media":"浦东发布","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575237445?lang=zh_cn&edition=fundamental","pubTime":"2025-10-13 20:47","pubTimestamp":1760359621,"startTime":"0","endTime":"0","summary":"10月13日，上海生物医药创新成果展与2025上海国际生物医药产业周同期在浦东张江举办。一批浦东“明星药械”集中亮相上海生物医药创新成果展。成果展数据显示，2021年至2025年9月，上海获批上市国产1类创新药合计30个；获批上市境内第三类创新医疗器械数量达45个。在获批名单上，浦东企业占据重要份额。在全球市场展现中国创新药非凡竞争力非凡的产业成就离不开基础研究强大的策源功能和转化支撑。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251013205854a6b724e0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251013205854a6b724e0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1515","BK1161","02591","BK1574","BK1583","06978","01877"],"gpt_icon":0},{"id":"2574397974","title":"银诺医药-B10月08日主力净流出121.8万元 散户资金买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2574397974","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574397974?lang=zh_cn&edition=fundamental","pubTime":"2025-10-08 16:15","pubTimestamp":1759911356,"startTime":"0","endTime":"0","summary":"10月08日, 银诺医药-B股价跌4.82%，报收39.50元，成交金额1224.4万元，换手率0.07%，振幅5.54%，量比0.65。银诺医药-B今日主力资金净流出121.8万元，上一交易日主力净流出0万元。该股近5个交易日下跌3.75%，主力资金累计净流入19.5万元；近20日主力资金累计净流出229.8万元，其中净流出天数为8日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251008162054a456f026&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251008162054a456f026&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02591","BK1161"],"gpt_icon":0},{"id":"2572502048","title":"银诺医药-B10月03日获主力加仓191.2万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2572502048","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572502048?lang=zh_cn&edition=fundamental","pubTime":"2025-10-03 16:16","pubTimestamp":1759479362,"startTime":"0","endTime":"0","summary":"10月03日, 银诺医药-B股价涨1.91%，报收40.64元，成交金额2037.8万元，换手率0.12%，振幅8.27%，量比1.07。银诺医药-B今日主力资金净流入191.2万元，上一交易日主力净流入7.7万元。该股近5个交易日下跌2.73%，主力资金累计净流入182.9万元；近20日主力资金累计净流出3.9万元，其中净流出天数为7日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251003162140971e34d3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251003162140971e34d3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02591","BK1161"],"gpt_icon":0},{"id":"2571134119","title":"浦东生物医药企业竞逐“全球新”","url":"https://stock-news.laohu8.com/highlight/detail?id=2571134119","media":"新浪财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571134119?lang=zh_cn&edition=fundamental","pubTime":"2025-09-30 18:22","pubTimestamp":1759227774,"startTime":"0","endTime":"0","summary":"今年以来，浦东生物医药企业资本市场表现活跃：劲方医药、银诺医药已赴港上市，多家企业密集递交申请。自2018年君实生物成为张江药谷首家港股18A上市企业后，浦东药企赴港上市热潮涌动，产业正从“量变”迈向“质变”。出海方面，今年上半年浦东生物医药企业出海交易近30起，交易额占全国31%、全球14%。据悉，浦东将在2025上海国际生物医药产业周期间，围绕“源头创新 链聚全球”推出更多服务与政策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250930183301954e19e0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250930183301954e19e0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01877","BK1161","BK1515","BK1574","09939","02595","02591"],"gpt_icon":1},{"id":"2571103383","title":"银诺医药-B(02591)已在中国完成核心产品(即依苏帕格鲁肽α)用于治疗肥胖和超重的III期临床试验的首例患者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2571103383","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571103383?lang=zh_cn&edition=fundamental","pubTime":"2025-09-30 17:05","pubTimestamp":1759223106,"startTime":"0","endTime":"0","summary":"智通财经APP讯，银诺医药-B(02591)发布公告，于2025年9月30日，公司已在中国完成核心产品(即依苏帕格鲁肽α)用于治疗肥胖和超重的III期临床试验的首例患者给药。公司计划就该临床试验招募大约800位参与者。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1351279.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02591","BK4134","BK1161","III"],"gpt_icon":0},{"id":"2572532227","title":"银诺医药-B09月30日主力净流出57.6万元 散户资金买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2572532227","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572532227?lang=zh_cn&edition=fundamental","pubTime":"2025-09-30 16:15","pubTimestamp":1759220131,"startTime":"0","endTime":"0","summary":"09月30日, 银诺医药-B股价跌4.19%，报收39.32元，成交金额1656.3万元，换手率0.10%，振幅4.97%，量比0.90。银诺医药-B今日主力资金净流出57.6万元，上一交易日主力净流入41.7万元。该股近5个交易日下跌5.48%，主力资金累计净流出16.0万元；近20日主力资金累计净流出187.0万元，其中净流出天数为8日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250930161741a6a7fafe&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250930161741a6a7fafe&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02591","BK1161"],"gpt_icon":0},{"id":"2571515513","title":"银诺医药-B：二零二五年中期报告","url":"https://stock-news.laohu8.com/highlight/detail?id=2571515513","media":"香港交易所","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571515513?lang=zh_cn&edition=fundamental","pubTime":"2025-09-29 18:12","pubTimestamp":1759140750,"startTime":"0","endTime":"0","summary":"银诺医药2025年上半年实现收入人民币5644.6万元，主要来自依苏帕格鲁肽α在中国的商业化销售。此外，公司已于3月在中国启动该药物用于治疗肥胖和超重的IIb/III期临床试验，预计2026年第四季度完成。截至2025年6月30日，公司现金及现金等价物为5.38亿元。公司将积极推进依苏帕格鲁肽α的全球扩张，推进肥胖及超重适应症的临床开发，并持续推动该药物纳入国家医保目录。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025092918200397b0b7e2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025092918200397b0b7e2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02591","BK1161"],"gpt_icon":0},{"id":"2571535136","title":"减肥神药核心专利明年到期，中国药企围剿全球药王","url":"https://stock-news.laohu8.com/highlight/detail?id=2571535136","media":"腾讯财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571535136?lang=zh_cn&edition=fundamental","pubTime":"2025-09-29 10:06","pubTimestamp":1759111613,"startTime":"0","endTime":"0","summary":"2025年上半年，它以165亿美元的销售额，登顶全球“药王” 。司美格鲁肽核心化合物专利将在2026年后在等多个国家到期，这意味着届时一大批价格便宜得多的类似药将迎来上市潮。中国将是第一个专利到期的国家。2025年上半年，替尔泊肽的全球销售额超过140亿美元，紧随司美格鲁肽和K药跻身全球最畅销药品前三。有逾120种药物处于临床开发阶段，约30%为中资药企。预计至2030年，中国GLP-1药物市场规模有望突破330亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250929103108954b4b19&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250929103108954b4b19&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","01801","02591"],"gpt_icon":0},{"id":"2569750924","title":"港股医药新锐布局AI","url":"https://stock-news.laohu8.com/highlight/detail?id=2569750924","media":"药智网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569750924?lang=zh_cn&edition=fundamental","pubTime":"2025-09-23 10:03","pubTimestamp":1758592982,"startTime":"0","endTime":"0","summary":"9月22日，银诺医药宣布与迈富时达成战略合作。银诺医药也因此成为全球第三家、亚洲首家在商业化阶段拥有自主知识产权的企业。银诺医药此次跨界合作，通过AI赋能，有望在医患服务、市场洞察等方面实现“弯道超车”，增强市场竞争力。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250923100538a43d86c4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250923100538a43d86c4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02591","BK1161","BK1109","BK1618","BK1518","02556"],"gpt_icon":0},{"id":"2569782945","title":"银诺医药-B09月22日主力净流入176.1万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2569782945","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569782945?lang=zh_cn&edition=fundamental","pubTime":"2025-09-22 16:15","pubTimestamp":1758528952,"startTime":"0","endTime":"0","summary":"09月22日, 银诺医药-B股价涨0.10%，报收42.14元，成交金额1971.9万元，换手率0.11%，振幅5.23%，量比0.78。银诺医药-B今日主力资金净流入176.1万元，上一交易日主力净流出199.5万元。该股近5个交易日下跌4.96%，主力资金累计净流出112.9万元，其中1个交易日为股价上涨时净流出；近20日主力资金累计净流出290.4万元，其中净流出天数为9日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025092216213697a1f79e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025092216213697a1f79e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02591","BK1161"],"gpt_icon":0},{"id":"2569272839","title":"迈富时携手银诺医药，以AI智能体驱动医药行业全链路智能升级","url":"https://stock-news.laohu8.com/highlight/detail?id=2569272839","media":"证券市场周刊","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569272839?lang=zh_cn&edition=fundamental","pubTime":"2025-09-22 09:13","pubTimestamp":1758503580,"startTime":"0","endTime":"0","summary":"迈富时认为，本次合作不仅是AI智能体技术在医药行业的一次深度应用，也是公司“多行业智能体生态共建”战略的重要实践。未来，双方将以AI智能体为技术基础，以医疗场景价值为牵引，持续推动医药行业的服务模式重构与组织效率提升，构建更加精准、普惠、高效的数智医药新生态。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250922091507a72e1ef8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250922091507a72e1ef8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1109","02591","BK1161","BK1518","BK1618","02556"],"gpt_icon":0},{"id":"2568947607","title":"银诺医药-B09月18日主力净流出82.7万元 散户资金买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2568947607","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2568947607?lang=zh_cn&edition=fundamental","pubTime":"2025-09-18 16:15","pubTimestamp":1758183356,"startTime":"0","endTime":"0","summary":"09月18日, 银诺医药-B股价跌3.59%，报收43.50元，成交金额2208.0万元，换手率0.12%，振幅6.56%，量比0.82。银诺医药-B今日主力资金净流出82.7万元，上一交易日主力净流入37.7万元。该股近5个交易日上涨2.69%，主力资金累计净流出82.6万元，其中2个交易日为股价下跌时净流入；近20日主力资金累计净流出313.1万元，其中净流出天数为9日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250918162329979a97aa&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250918162329979a97aa&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02591"],"gpt_icon":0},{"id":"2568247982","title":"广州创新药，创造38亿账面回报","url":"https://stock-news.laohu8.com/highlight/detail?id=2568247982","media":"投中网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2568247982?lang=zh_cn&edition=fundamental","pubTime":"2025-09-18 15:14","pubTimestamp":1758179688,"startTime":"0","endTime":"0","summary":"最引人注目的，当属创新药公司银诺医药在8月15日的IPO。按照银诺医药发行价每股18.68港元计算，银诺医药已经为投资方创造了38.60亿元的账面退出回报。它们为VC/PE机构创造的账面退出金额为83亿元，同比下降44.30%，环比下降86.68%；平均账面回报率为1.26倍。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202509181515529535e1b8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202509181515529535e1b8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02591","06978","BK1161","BK1574"],"gpt_icon":0},{"id":"2567661127","title":"港股异动 | 银诺医药-B(02591)涨超4% 核心产品依苏帕格鲁肽α在澳门正式进入商业化销售阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2567661127","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2567661127?lang=zh_cn&edition=fundamental","pubTime":"2025-09-16 10:28","pubTimestamp":1757989724,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，银诺医药-B(02591)涨超4%，截至发稿，涨4.42%，报46.3港元，成交额1258.52万港元。消息面上，银诺医药-B发布公告，公司一直积极推进其核心产品(即依苏帕格鲁肽α)的全球扩张，并于2025年6月在中华人民共和国澳门特别行政区(澳门)获得核心产品用于治疗2型糖尿病(T2D)的BLA(生物制品许可申请)批准。公司董事会欣然宣布，于2025年9月12日，公司用于治疗2型糖尿病的核心产品于澳门的首张处方已在澳门华宝医疗中心开出，标志着核心产品在澳门正式进入商业化销售阶段。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1345636.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4614","BK1161","YANG","HSCEI","02591"],"gpt_icon":0},{"id":"2567155770","title":"银诺医药(02591.HK)核心产品在澳门正式进入商业化销售","url":"https://stock-news.laohu8.com/highlight/detail?id=2567155770","media":"阿斯达克财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2567155770?lang=zh_cn&edition=fundamental","pubTime":"2025-09-14 19:13","pubTimestamp":1757848380,"startTime":"0","endTime":"0","summary":"银诺医药－Ｂ(02591.HK) 公布，公司用于治疗2型糖尿病的核心产品依苏帕格鲁肽α于澳门的首张处方已在澳门华宝医疗中心开出，标志着核心产品在澳门正式进入商业化销售阶段。(de/d)(港股报价延迟最少十五分钟。)AASTOCKS新闻","market":"fut","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20250815144634160_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20250815144634160_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1470121/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1161","02591"],"gpt_icon":0},{"id":"2566974995","title":"银诺医药-B(02591.HK)用于治疗2型糖尿病的核心产品于澳门的首张处方已在澳门华宝医疗中心开出","url":"https://stock-news.laohu8.com/highlight/detail?id=2566974995","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566974995?lang=zh_cn&edition=fundamental","pubTime":"2025-09-12 21:06","pubTimestamp":1757682398,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["159891","BK1161","02591"],"gpt_icon":0},{"id":"2566897499","title":"银诺医药-B(02591)用于治疗2型糖尿病的核心产品于澳门的首张处方已在澳门华宝医疗中心开出","url":"https://stock-news.laohu8.com/highlight/detail?id=2566897499","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566897499?lang=zh_cn&edition=fundamental","pubTime":"2025-09-12 21:06","pubTimestamp":1757682398,"startTime":"0","endTime":"0","summary":"智通财经APP讯，银诺医药-B(02591)发布公告，公司一直积极推进其核心产品(即依苏帕格鲁肽α)的全球扩张，并于2025年6月在中华人民共和国澳门特别行政区(澳门)获得核心产品用于治疗2型糖尿病(T2D)的 BLA(生物制品许可申请)批准。公司董事会欣然宣布，于2025年9月12日，公司用于治疗2型糖尿病的核心产品于澳门的首张处方已在澳门华宝医疗中心开出，标志着核心产品在澳门正式进入商业化销售阶段。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1344834.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02591","159891","BK1161"],"gpt_icon":0},{"id":"2566892614","title":"浙商“股道行”||深耕江浙8月投研活动","url":"https://stock-news.laohu8.com/highlight/detail?id=2566892614","media":"浙商证券研究所","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566892614?lang=zh_cn&edition=fundamental","pubTime":"2025-09-09 22:01","pubTimestamp":1757426482,"startTime":"0","endTime":"0","summary":"浙商研究持续推进“深耕江浙”战略，覆盖江浙超90%的优质上市企业。8月，浙商紧跟创新药/无人车/游戏产业等热点，开展“股道行”江浙沪调研20+次，参与100+人次。研途观察随着无人车技术日渐成熟，快递无人车正从“技术验证”阶段迈向“商业正循环”，在政策开放加速度、成本不断下降等合力驱动下，行业有望于2025年迎来规模化商用拐点。品牌层面持续推动年轻化战略，通过跨界联名、校园活动及社媒互动强化与年轻群体联结。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250909220903a719cd77&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250909220903a719cd77&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1255","02643","BK1521","IE00BZ08YS42.EUR","01177","BK1588","IE00B29SXG58.USD","BK1161","BK1151","BK1589","BK1574","IE00BZ08YR35.GBP","BK1515","BK1237","02057","IE00BZ08YT58.USD","BK1575","BK1541","BK1191","02591","09985","BK1502","06978"],"gpt_icon":0},{"id":"2564843893","title":"银诺医药-B(02591)认购结构性存款产品","url":"https://stock-news.laohu8.com/highlight/detail?id=2564843893","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564843893?lang=zh_cn&edition=fundamental","pubTime":"2025-09-01 22:35","pubTimestamp":1756737302,"startTime":"0","endTime":"0","summary":"智通财经APP讯，银诺医药-B(02591)发布公告，于2025年8月18日，银诺技术(公司直接全资附属公司)以人民币3000万元的代价(即其本金额)向招商银行认购招商银行结构性存款产品。于2025年9月1日，公司及银诺技术(公司一间直接全资附属公司)以代价合共人民币1.05亿元(即其总本金额)向宁波银行认购一项宁波银行结构性存款产品。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1340228.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02591"],"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":2,"totalSize":102,"code":"91000000","status":"200"}]}}